The EC has approved BMS Opdivo in combination with Yervoy as a first-line treatment for adults with unresectable or advanced HCC.

Acquisition of the constitutively active Janus kinase 2 (JAK2)V617F mutation occurs in almost all patients with polycythaemia vera (PV) and in a significant number of patients with essential ...

In mouse thymocytes, positive regulation of inducible T cell kinase (ITK) membrane recruitment by InsP 4 establishes a feedback loop of phospholipase Cγ1 activation downstream of the T cell ...

The combined use of two well-known active substances can fight leukemic cells and limit their spread. This is the result of a study conducted by the Karl Landsteiner University of Health Sciences ...

Objectives: This study aimed to identify, measure and evaluate expected costs of innovative palonosetron-based antiemetic therapy versus ondansetron-based treatment, the ultimate aim being to ...

Immunotherapy has revolutionized the treatment landscape for various adult solid tumors, harnessing the body's immune system to combat cancer. However, pediatric cancers present unique challenges due ...

Sanofi’s Sarclisa has received approval in more than 50 nations and regions. Credit: LCV/Shutterstock. Sanofi’s Sarclisa (isatuximab) has gained approval from Japan’s Ministry of Health, Labour and ...

Tezspire targets the airway epithelium, the primary source of inflammation. Credit: Emily Frost / Shutterstock. Amgen and AstraZeneca have reported complete outcomes from the registrational Phase III ...

OHSU Doernbecher is a national leader in care for pediatric leukemia. We are the only children’s hospital in Oregon to offer CAR T-cell therapy, a groundbreaking treatment for childhood leukemia. Like ...

Department of Chemistry, College of Science, King Faisal University, Al-Ahsa 31982, Saudi Arabia ...